The upregulation of OLFML2B increases the stromal scores by recruiting cancer-associated fibroblasts and other stromal cells, which have been proven to promote tumorigenesis, tumor angiogenesis, neoplasm metastasis, and drug resistance, especially in ESCA, KIRC, LIHC, STAD, and LGG. This evidence concerns the gene OLFML2B and neoplasm.